Financière de Tubize SA Insider ownership
What is the Insider ownership of Financière de Tubize SA?
The Insider ownership of Financière de Tubize SA is 56.85%
What is the definition of Insider ownership?
Insider Ownership is calculated as the total number of shares owned by insiders (shareholders who own more than 5% of the corporation or an officer or director of the company) divided by the total Shares Outstanding.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Insider ownership of companies in the Health Care sector on EURONEXT compared to Financière de Tubize SA
What does Financière de Tubize SA do?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Companies with insider ownership similar to Financière de Tubize SA
- Las Vegas Sands has Insider ownership of 56.80%
- Kakatiya Cement Sugar and Industries has Insider ownership of 56.81%
- McChip Resources has Insider ownership of 56.82%
- Laurus Labs has Insider ownership of 56.83%
- Reitmans (Canada) has Insider ownership of 56.84%
- Tecnoglass Inc has Insider ownership of 56.85%
- Financière de Tubize SA has Insider ownership of 56.85%
- Fairfax Africa has Insider ownership of 56.86%
- Conart Engineers has Insider ownership of 56.86%
- Moelis Australia has Insider ownership of 56.86%
- Western Pacific Trust has Insider ownership of 56.87%
- Crexendo has Insider ownership of 56.88%
- Helios Fairfax Partners has Insider ownership of 56.88%